HopeStage
Back to all studies
Not recruitingISRCTN11177045

IVIG and rituximab in antibody-associated psychosis - SINAPPS2

Research studyAges 16–70United KingdomSchizophrenia
The study in practice

Understand this study

Who could participate?

Listed age limits: 16 years to 70 years.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: November 1, 2017
Recruitment status
Not recruiting
Enrollment listed in the registry
Not clearly listed
Sponsor
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
Sponsor type
University
Study type
Other
Intervention type
Other / unclear
Locations
United Kingdom
Age range
From 16 Years to 70 Years
Official registry ID
ISRCTN11177045
Official title
Show the full official title

A Randomised Phase II Double-blinded Placebo-controlled Trial of Intravenous Immunoglobulins and Rituximab in Patients With Antibody-associated Psychosis (SINAPPS2)

Recruitment & locations

Not recruiting

Cambridge · Exeter · Glasgow

6 more locations
  • Liverpool
  • London
  • Manchester
  • Nottingham
  • Oxford
  • Sheffield

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, a university.

Who can participate?

Listed age limits: 16 years to 70 years.

Is this study still recruiting?

The registry lists this study as not recruiting.

Want to explore more studies?

Explore studies